Institutional Ownership
Galera Therapeutics Equiclass Equity
CUSIP 36338D108COMMON STOCKQ1 2026
13D / 13G Filings
35
Schedule 13D/13G on record
Beneficial Filers
18
Distinct reporting persons
Largest Stake
19.9%
Max % of class reported
Institutional Holders
1
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
35 filings · latest Feb 14, 2025
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 14, 2025 | Ikarian Capital, LLC | 13G | 11.0% | 7.54M | SEC |
| 2 | May 16, 2024 | Schneid Yair | 13G/A | 19.9% | 10.82M | SEC |
| 3 | May 16, 2024 | Soffer Rochel | 13G | 10.9% | 5.93M | SEC |
| 4 | May 1, 2024 | Schneid Yair | 13G/A | 19.9% | 10.82M | SEC |
| 5 | Apr 16, 2024 | Alpha Pharma Investments LLC | 13G | 5.1% | — | SEC |
| 6 | Apr 3, 2024 | Altamont Pharmaceutical Holdings, LLC | 13G/A | — | — | SEC |
| 7 | Feb 20, 2024 | Sofinnova Venture Partners Ix, L.P. | 13D/A | — | — | SEC |
| 8 | Feb 14, 2024 | Sectoral Asset Management Inc | 13G/A | — | — | SEC |
| 9 | Jan 17, 2024 | Schneid Yair | 13G | 13.1% | 7.11M | SEC |
| 10 | Dec 4, 2023 | Blackstone Holdings I/II Gp L.L.C. | 13D/A | 1.0% | 542.6K | SEC |
25 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Galera Therapeutics Equiclass Equity.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Ascentis Independent Advisors | 93 | $4 |